Q2 2026 Financial Results

August 6, 2026

SKINHEALTH
SYSTEMS

Disclaimer

This Presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, expectations of future operating results or financial performance of SkinHealth Systems Inc. (the "Company"), capital expenditures, the introduction of new products, market strategy and the ability to execute certain strategic initiatives. Some of the forward-looking statements can be identified by the use of forward-looking words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “outlook,” “forecast” and other similar expressions. These are intended to identify forward-looking statements. All forward-looking statements are based upon management estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company as of the date of this Presentation. Any such estimates, assumptions, expectations, forecasts, views or opinions set forth in this Presentation constitute the Company’s judgments and should be regarded as indicative, preliminary and for illustrative purposes only. The forward-looking statements and projections contained in this Presentation are not guarantees of future performance, conditions or results, and are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause the Company’s actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition. Although such forward-looking statements have been made in good faith and are based on assumptions we believe to be reasonable, there is no assurance that the expected results will be achieved. Many factors could adversely affect our business and financial performance. We discussed a number of material risks in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2026, and in our subsequent filings with the SEC. Those risks continue to be relevant to our performance and financial condition. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time-to-time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We expressly disclaim any responsibility to update forward-looking statements, whether as a result of new information, future events or otherwise. All material non-public information in this presentation has been simultaneously disclosed in the earnings press release or has otherwise been made public.

Non-GAAP Financial Measures

In addition to results determined in accordance with accounting principles generally accepted in the United States of America ("GAAP"), management utilizes certain non-GAAP financial measures such as adjusted gross profit, adjusted gross margin, adjusted EBITDA, and adjusted EBITDA margin for purposes of evaluating ongoing operations and for internal planning and forecasting purposes. Management believes that these non-GAAP financial measures, when reviewed collectively with the Company’s GAAP financial information, provide useful supplemental information to investors in assessing the Company's operating performance. These non-GAAP financial measures should not be considered as an alternative to GAAP financial information or as an indication of operating performance or any other measure of performance derived in accordance with GAAP, and may not provide information that is directly comparable to that provided by other companies in its industry, as these other companies may calculate non-GAAP financial measures differently, particularly related to unusual items.

Adjusted gross profit is gross profit excluding the effects of depreciation expense, amortization expense, share-based compensation expense and other long-term incentive compensation. Adjusted gross margin represents adjusted gross profit as a percentage of net sales.

Adjusted operating expenses is calculated as total operating expenses excluding the effects of depreciation expense; amortization expense; share-based compensation expense and other long-term incentive compensation; litigation related costs; Go-to-Market restructuring; and severance, restructuring, and other.

Adjusted EBITDA is calculated as net (loss) income excluding the effects of expense (benefit) for income taxes; depreciation expense; amortization expense; share-based compensation expense and other long-term incentive compensation; interest expense; interest income; other income, net; change in fair value of warrant liabilities; foreign currency loss (gain), net; litigation related costs; Go-to-Market restructuring; and severance, restructuring and other. Adjusted EBITDA margin represents adjusted EBITDA as a percentage of net sales.

The Company does not provide a reconciliation of its fiscal 2026 adjusted EBITDA guidance to net (loss) income, the most directly comparable forward looking GAAP financial measures, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, which cannot be done without unreasonable efforts, including adjustments that could be made for changes in fair value of warrant liabilities, integration and acquisition-related expenses, amortization expenses, non-cash share-based compensation, gains/losses on foreign currency, and other charges reflected in our reconciliation of historic numbers, the amount of which, based on historical experience, could be significant. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. The Company's fiscal 2026 adjusted EBITDA guidance is merely an outlook and is not a guarantee of future performance. Stockholders should not rely or place an undue reliance on such forward-looking statements. See “Forward-Looking Statements” for additional information.

Strategic Objective

Establish SkinHealth Systems as a leader in medical aesthetics, delivering an ecosystem of solutions that uniquely combines devices, consumables, clinical credibility, and brand power to achieve superior skin health for consumers and positive economic outcomes for providers.

The Global Medical Aesthetics Market

Growing & Increasingly Favorable to SkinHealth Systems

Large and addressable global market driven by innovation

Clinical credibility and efficacy increasingly drive provider and consumer product choice[1]

Skin health is becoming a lifestyle category

Combination treatments increasing in popularity, driving consumer satisfaction[2]

Broadening consumer demographics – Men, Gen Z, and younger consumers

Consumer preference shifting toward skin quality treatments[2]

1. Euromonitor. Voice of the Consumer: Beauty Survey, fielded May 2025. N=20,206.
2. BCG. Medical Aesthetics Provider and Consumer Surveys across ~10,000 respondents; BCG analysis. IMCAS. January 2026

Opportunity to leverage our assets to drive profitable growth

COMPELLING BRAND EQUITY IN LARGE, ADDRESSABLE MARKET

Hydrafacial is the #2 most recognized brand in aesthetics[1] with an accessible price point for consumers and immediately gratifying results

LOYAL PROVIDERS

Valued by providers for attractive economics with equipment payback in as little as 6-9 months[2], and ability to bundle with other services

HYDRODERMABRASION MARKET LEADER

Category strong-hold and omnichannel distribution provides structural advantages



ATTRACTIVE ECONOMIC MODEL

Profitable unit economics on equipment sales and long-tailed, durable recurring cash flow from consumables sales

GROWING GLOBAL FOOTPRINT

36,000+ active devices provide base of cash flow and opportunity to grow ecosystem

1. Ipsos Study 2025. Base: Consumers of the aesthetic and professional beauty category (n=1000); Brand Aided Awareness.
2. Payback calculations and gross annual income based on providing 5-10 Deluxe Hydrafacial treatments a week at SRP of $250 per treatment and working 25 weeks to 50 weeks in the year, respectively.

Roadmap to Accelerate Growth

PHASE 1 Stabilize & Invest in Innovation | **PHASE 2** Launch New Products | **PHASE 3** Accelerate

CURRENTLY EXECUTING PHASE 1

Strengthening the Core Hydrafacial Franchise

Launching new U.S. device rental program expected in Q3 2026 to make Hydrafacial accessible to more practices.

Developing next-generation Hydrafacial device planned for 2028.

Increasing the Value of the Hydrafacial Device Footprint

Anticipated launch of next clinically validated booster in Q4 2026, with additional innovations planned throughout 2027.

Reposition HydraScalp with Keravive to extend presence into the growing scalp and hair wellness category.

Expand Into Attractive Adjacent Categories

Extend SkinStylus microneedling offering.

Continue strategic plan to identify, test, and bring a complementary modality device to the U.S. market in 2027.

Skin Health Benefits Beyond the Face: HydraScalp® with Keravive™

Reintroduction of Scalp Health Offering

- Advanced, non-invasive scalp treatment with no downtime powered by Hydrafacial's proprietary Vortex-Fusion Technology

The Skinification of the Scalp

- 73% of consumers are concerned about scalp health and hair growth[1]
- 76% of consumers are interested in an in-office treatment that can help with these concerns[1]

Clinically Proven Results

- In a clinical study, 75% of users reported fuller-looking hair, and 82% reported shinier, healthier-looking strands after a series of treatments[2]

[1] NewBeauty Beauty Engine Survey, January 2026 (N=1,464)
[2] Kilmer S, Shamban AT, Callender VD, Jalian HR, Karnik J. Clinical Evaluation of the Effectiveness and Safety of an In-Office Scalp Stimulating Treatment and a Take-Home Scalp Health Product. HydraFacial LLC. 2019
Based on perception of 44 participants receiving a series of 3 Hydrafacial Keravive treatments with daily application of take-home peptide spray in between treatments for 20 weeks.

Microneedling with SkinStylus®



Adjacent Category with Growth Potential
Microneedling is one of the fastest growing categories in medical aesthetics[1]

Clinically Proven Skin Health Solution
SkinStylus reduces the appearance of fine lines and periorbital wrinkles[2]

Versatile and Flexible Device
Microneedling and nano-channeling options to help address a wide range of skin concerns

Complementary to Hydrafacial
As a standalone treatment or in combination protocols

The Only Microneedling Device with Indications for Facial Acne Scars, Periorbital Wrinkles, and Abdominal Scars

[1] Guidepoint Qsight - Sales Measurement from Full Year 2025. Qsight Sales Measurement data is based on point-of-sale transactions from 3,400+ US Aesthetics practice locations.
[2] Clinical Investigation Report: Evalution of the Efficacy and Safety of the SkinStylus SteriLock Mircorneedling System for the reatment of facial wrinkles. Rev 4, 2025.N=51 enrolled (50 completed) across 2 U.S. sites. Wrinkle severity assessed using the Lemperle Wrinkle Grading Scale at Baseline, Day 120 and Day 150.



SKINHEALTH SYSTEMS

Corporate Rebrand in Q2 2026

"This is not simply a change in name. It represents a fundamental evolution in how we operate, and how we intend to compete. Our focus is on building a durable, scalable ecosystem of skin health technologies and solutions that delivers consistent, provider-led outcomes and creates long-term value for our customers and stakeholders.“

- Pedro Malha, SkinHealth Systems CEO

Q2 2026 Financial Highlights and Guidance

Second Quarter 2026 Financial Highlights

Net Sales	Delivery Systems Net Sales	Consumables Net Sales	Net Income (Loss)	Adjusted EBITDA[1]
$72.1m	$18.3m	$53.9m	$(2.7)m	$17.0m
-7.8% YoY	-18.4% YoY	-3.5% YoY	-$22.4m YoY	+$3.1m YoY
Primarily impacted by reduced delivery system placements and lower consumables sales.	Decrease in delivery systems net sales, as challenging market conditions persist.	Decrease in consumables net sales due to pressure on treatment volume and timing of prior year booster launches.	Change primarily due to $18.1 million net gain related to the exchange and repurchases of the 2026 Notes in Q2 2025.	Increase due to lower adjusted operational spend and higher gross margin, partially offset by lower net sales.

1. Non-GAAP measure; please refer to the appendix for a reconciliation to the appropriate GAAP measure.

SKINHEALTH SYSTEMS

Revised 2026 Financial Guidance

3Q 2026

$65 – $70m

3Q 2026E net sales

$5 – $7m

3Q 2026E adjusted EBITDA[1]

FY 2026

$280 – $290m

FY 2026E net sales

$39 – $46m

FY 2026E adjusted EBITDA[1]

1. Adjusted EBITDA is a non-GAAP measure; please refer to the disclaimer for a discussion of the definition of this measure and important information regarding the assumptions underlying the outlook.

Appendix: Non-GAAP Financial Reconciliations

Reconciliation of gross profit to adjusted gross profit

	Three Months Ended June 30,		Six Months Ended June 30,	
Unaudited ($ in millions) [1]	**2026**	**2025**	**2026**	**2025**
Net sales	$ 72.1	$ 78.2	$ 137.0	$ 147.8
Gross profit	$ 49.3	$ 49.1	$ 93.8	$ 97.7
Gross margin	68.4%	62.8%	68.4%	66.1%
Adjusted to exclude the following:				
Depreciation expense	0.2	0.2	0.4	0.4
Amortization expense	2.1	2.1	4.2	3.1
Share-based compensation expense and other long-term incentive compensation [2]	0.1	0.1	0.2	0.3
Adjusted gross profit	$ 51.8	$ 51.5	$ 98.7	$ 101.6
Adjusted gross margin	71.8%	65.9%	72.0%	68.7%

1 Amounts may not sum due to rounding
2 Includes expense associated with long-term cash performance awards that can be settled in either cash or Common Stock

Reconciliation of operating expenses to adjusted operating expenses

Unaudited ($ in millions) [1]	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
Total operating expenses	$ 45.8	$ 51.8	$ 92.0	$ 112.4
Adjusted to exclude the following:				
Depreciation expense	0.3	0.5	0.7	2.1
Amortization expense	2.6	2.6	5.3	5.9
Share-based compensation expense and other long-term incentive compensation [2]	2.8	5.2	4.8	8.5
Litigation related costs [3]	4.9	5.0	7.0	11.9
Go-to-Market restructuring [4]	(0.2)	0.2	-	3.0
Severance, restructuring and other	0.5	0.6	1.0	0.6
Adjusted operating expenses	$ 34.8	$ 37.6	$ 73.1	$ 80.4

1 Amounts may not sum due to rounding
2 Includes expense associated with long-term cash performance awards that can be settled in either cash or Common Stock
3 Includes the proposed settlement in the Securities Class Action suit
4 Includes costs associated with transition to a distributor model in the China and Australia and New Zealand markets

SKINHEALTH SYSTEMS

Reconciliation of net income (loss) to adjusted EBITDA

Unaudited ($ in millions) [1]	**Three Months Ended June 30, 2026**	**Three Months Ended June 30, 2025**	**Six Months Ended June 30, 2026**	**Six Months Ended June 30, 2025**
Net sales	$ 72.1	$ 78.2	$ 137.0	$ 147.8
Net (loss) income	$ (2.7)	$ 19.7	$ (9.3)	$ 9.6
Net (loss) income margin	(3.7%)	25.2%	(6.8%)	6.5%
Adjusted to exclude the following:				
Expense (benefit) for income taxes	1.2	(1.0)	1.0	(0.1)
Depreciation expense	0.5	0.7	1.1	2.6
Amortization expense	4.7	4.7	9.5	9.0
Share-based compensation expense and other long-term incentive compensation [2]	3.0	5.3	5.1	8.8
Interest expense	6.3	4.1	12.6	6.6
Interest income	(1.3)	(3.2)	(2.8)	(6.2)
Other income, net	-	(18.1)	(1.1)	(18.2)
Change in fair value of warrant liabilities	-	0.2	-	(0.1)
Foreign currency loss (gain), net	-	(4.5)	1.2	(6.3)
Litigation related costs [3]	4.9	5.0	7.0	11.9
Go-to-Market restructuring [4]	(0.2)	0.2	-	3.0
Severance, restructuring and other	0.5	0.6	1.0	0.6
Adjusted EBITDA	$ 17.0	$ 13.9	$ 25.5	$ 21.2
Adjusted EBITDA margin	23.6%	17.8%	18.6%	14.3%

1 Amounts may not sum due to rounding
2 Includes expense associated with long-term cash performance awards that can be settled in either cash or Common Stock
3 Includes the proposed settlement in the Securities Class Action suit
4 Includes costs associated with transition to a distributor model in the China and Australia and New Zealand markets

SKINHEALTH SYSTEMS

SKINHEALTH

SYSTEMS